 Avalon GloboCare Corp NASDAQ:AVCO announced that it has further advanced its research to accurately predict the 3-dimensional structures of protein receptors for potential use as cellular therapy targets, in partnership with the Massachusetts Institute of Technology MIT. The Toronto-based company collaborated with the institute to combine its artificial intelligence AI-enhanced protein design QTY Code technology with Googles AlphaFold2, a DeepMind AI program developed to predict 3D protein structures of previously difficult to work with drug targets. 